- Combined immune checkpoint inhibition of CTLA-4 and PD-1 or PD-L1- Other immune therapies (i.e., CD47 blockade, bispecific antibodies targeting both tumor-specific antigen and NK cells)- PD-1 blockade combined with anti-LASG-3 antibody therapy- Targeted therapy (i.e., BV) combined with PD-1 blockade- PD-1 blockade in combination with chemotherapy in frontline setting. The gene discussed is CD274; the disease is neoplasm.